CARLSBAD, Calif. – April 19, 2018 – Ra Medical Systems, manufacturers of laser-based solutions for the treatment of cardiovascular and dermatological diseases, announced today that the Company has appointed Andrew Jackson as its Chief Financial Officer, effective immediately. Mr. Jackson has over 20 years of finance experience in life science and technology companies, including extensive experience with regulatory compliance, mergers and acquisitions, treasury management and capital and debt financing.
“Andrew is a perfect fit for Ra Medical, as he brings his broad financial experience in the life sciences industry to our rapidly growing team,” said Dean Irwin, Chief Executive Officer, Ra Medical. “His proven leadership and deep expertise will strengthen our Company moving forward.”
Mr. Jackson joins Ra Medical from AltheaDx, where he served as Chief Financial Officer leading the company’s financing activities. Prior to AltheaDx, he was Chief Financial Officer at Celladon Corporation, a publicly traded, clinical-stage biotechnology company; during his time there, Mr. Jackson scaled the company through its growth, leading Celladon’s public company compliance following its Initial Public Offering (IPO) and completing the company’s accretive merger with Eiger Biopharmaceuticals. Prior to Celladon, Mr. Jackson also held senior finance positions at various life science and technology companies.
“I’m eager to hit the ground running and join Ra Medical at such an exciting time in the Company’s lifecycle, especially given the recent FDA market clearance of our DABRA System as a treatment for peripheral artery disease,” added Mr. Jackson. “I’m delighted to join this dynamic team and hope to be a key asset to the Company’s strategic and financial initiatives.”
Mr. Jackson holds a B.S.B. in Accounting from the University of Minnesota and M.S.B.A. in Finance from San Diego State University. He is also a Certified Public Accountant.
About Ra Medical Systems
Ra Medical Systems was founded in 2002 to commercialize excimer lasers and catheters for the treatment of dermatologic and cardiovascular diseases. Its flagship product, Pharos, launched in 2004 and treats chronic dermatological diseases including psoriasis and vitiligo. Today, Ra Medical Systems is focused on the DABRA laser which is transforming endovascular therapy with its treatment of complex and diffuse arterial blockages.
For more information:
President, Ra Medical Systems